WHO Pharmaceuticals Newsletter 2003, No. 05
(2003; 15 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentASTEMIZOLE - Withdrawn due to ventricular arrhythmias
View the documentBICALUTAMIDE - Withdrawn due to accelerated deaths
View the documentDACLIZUMAB - Warning about hypersensitivity reactions, increased mortality in cardiac transplant study
View the documentDANAZOL - Use restricted to second-line therapy in endometriosis
View the documentLEVACETYL-METHADOL - Product to be withdrawn due to adverse cardiac events; safer alternatives to be adopted
View the documentMOROCTOCOG ALFA - Reports of lack of effect in prophylaxis patients
View the documentNEFAZODONE - Sale discontinued due to adverse hepatic events
View the documentNIMESULIDE - Product under ‘special pharmacovigilance’
View the documentOSELTAMIVIR - Adverse reactions section to include acute renal failure, thrombocytopenia, leucopenia
View the documentPHENYLPROPAN-OLAMINE - New warnings on cardiovascular risks to be added
View the documentSOMATROPIN - Refused approval for use in AIDS-related wasting syndrome
View the documentTERFENADINE - Withdrawn due to ventricular arrhythmias
View the documentVALSARTAN - Reports of interstitial pneumonia
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsDRUGS OF INTEREST
Open this folder and view contentsFEATURE
Open this folder and view contentsMISCELLANY
 

DACLIZUMAB - Warning about hypersensitivity reactions, increased mortality in cardiac transplant study

USA. The US prescribing information for daclizumab (Zenapax) has been updated to include two new warning statements regarding increased mortality seen in a cardiac transplant study and hypersensitivity reactions. Roche Pharmaceuticals has issued a ‘Dear Healthcare Professional’ letter informing prescribers of the updates. The addition of information to the ‘Warnings’ section of the product label regarding increased mortality reflects the findings of a randomised, double-blind, placebo-controlled trial of daclizumab (Zenapax) for the prevention of allograft rejection, in which 434 cardiac transplant recipients received concomitant cyclosporin, mycophenolate mofetil and corticosteroids. In the study, increased mortality was seen at 6 and 12 months in patients receiving daclizumab (Zenapax) compared with those receiving placebo (7% vs 5% and 10% vs 6%, respectively). Some of the increased mortality appeared to be related to a higher incidence of severe infection. Other sections of the product (Zenapax) labelling affected by the addition of this information have also been updated. Current information relating to the risk of hypersensitivity reactions has also been added to the ‘Warnings’ section, which states that severe, acute (onset within 24 hours) hypersensitivity reactions including anaphylaxis have been observed both on initial exposure and following re-exposure to the product. Permanent discontinuation of daclizumab is advised in the event of a severe hypersensitivity reaction.

Reports in WHO-file: Allergic reaction 3, anaphylactoid reaction 2

Reference:
‘Dear Healthcare Professional’ letter from Roche Pharmaceuticals, Aug 2003.
Available from URL:
http://www.fda.gov

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018